Financial Review: Anika Therapeutics (NASDAQ:ANIK) & Arvinas (NASDAQ:ARVN)

Arvinas (NASDAQ:ARVN) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Profitability

This table compares Arvinas and Anika Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arvinas	2.94%	1.91%	1.29%
Anika Therapeutics	-3.14%	0.20%	0.15%

Earnings & Valuation

This table compares Arvinas and Anika Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60 million	2.31	-$80.80 million	$0.10	93.90
Anika Therapeutics	$120.65 million	2.31	-$10.88 million	($0.27)	-77.07

Anika Therapeutics has lower revenue, but higher earnings than Arvinas. Anika Therapeutics is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Arvinas and Anika Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2	4	5	0	2.27
Anika Therapeutics	1	0	2	1	2.75

Arvinas currently has a consensus target price of $14.17, suggesting a potential upside of 50.87%. Anika Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 0.91%. Given Arvinas’ higher possible upside, analysts plainly believe Arvinas is more favorable than Anika Therapeutics.

Insider and Institutional Ownership

95.2% of Arvinas shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 7.3% of Arvinas shares are held by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Arvinas has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500.

Summary

Arvinas beats Anika Therapeutics on 10 of the 15 factors compared between the two stocks.

About Arvinas

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

About Anika Therapeutics

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company’s joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.